At a Glance
| Indication | Neurogenic bowel dysfunction |
| Drug | DTI-117 |
| Mechanism of Action | Neurokinin-2 receptor agonist |
| Company | Dignify Therapeutics |
| Trial Phase | Phase I |
| Category | Regulatory Milestone |
| Sub Category | Approval Granted |
| Therapeutic Area | Gastroenterology & Hepatology |
| Regulatory Body | US Food and Drug Administration (FDA) |
| Regulatory Action | Investigational New Drug (IND) Clearance |
| First Patient Dosed Target | November 2026 |
| Topline Data Anticipated | Early 2027 |
| Study Population | Healthy volunteers |
| Study Design | Double-blind, randomised, single-ascending-dose, placebo-controlled |
| Route of Administration | Intramuscular |
| Funding Source | National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke |
| NIH Award Number | U44NS129628 |
| Company Location | Research Triangle Park, North Carolina |
Dignify Therapeutics Gains FDA IND Clearance for DTI-117 Phase I
Dignify Therapeutics has received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) to initiate a Phase I trial for DTI-117. This drug candidate is being developed as an on-demand treatment for neurogenic bowel dysfunction (NBD). The company plans to administer the first dose to a healthy volunteer in November 2026, with initial topline findings anticipated in early 2027. The study will assess the tolerability, safety, and pharmacokinetics of single intramuscular doses of DTI-117, marking the company's transition from preclinical to clinical-stage development.
- DTI-117 is a novel short-acting peptide and neurokinin-2 receptor agonist, specifically engineered to induce rapid and controlled bowel evacuation within minutes. This mechanism aims to provide patients with greater command over the timing and setting of defecation, addressing a critical need for individuals with neurogenic bowel dysfunction.
- The upcoming Phase I trial will be a double-blind, randomised, single-ascending-dose, placebo-controlled study. Its primary objective is to evaluate the tolerability, safety, and pharmacokinetics of single intramuscular doses of DTI-117 in healthy volunteers, laying the groundwork for future efficacy studies in the target patient population.
- Dignify Therapeutics, based in Research Triangle Park, North Carolina, specializes in therapies for bowel and bladder voiding dysfunction in neurological patients. The development of DTI-117 has received significant financial backing, including funding from the National Institutes of Health (NIH) and the National Institute of Neurological Disorders and Stroke, contributing to over $20 million in NIH awards for the company.
Frequently Asked Questions
What are the significant clinical challenges in managing neurogenic bowel dysfunction?
Neurogenic bowel dysfunction presents complex challenges including chronic constipation, fecal incontinence, and abdominal pain, significantly impacting patient quality of life. Effective management requires addressing underlying neurological deficits and restoring coordinated bowel function. Current therapies often provide symptomatic relief but may not fully resolve the multifactorial nature of the condition.
How do novel therapeutic strategies, such as DTI-117, aim to address neurogenic bowel dysfunction?
Novel therapeutic strategies for neurogenic bowel dysfunction often focus on modulating specific neural pathways or restoring enteric nervous system function. DTI-117, for instance, may target key receptors or signaling cascades involved in gut motility and sensation. The goal is to provide more targeted and sustained improvements in bowel function compared to conventional symptomatic treatments.
What are the potential advantages of DTI-117 over existing treatments for neurogenic bowel dysfunction?
DTI-117 is designed to offer potential advantages by addressing the root causes of neurogenic bowel dysfunction rather than just managing symptoms. This could lead to more predictable bowel function, reduced reliance on invasive procedures, and improved patient autonomy. A targeted mechanism of action may also translate to a more favorable safety and tolerability profile.
What are the key regulatory considerations for bringing new treatments for neurogenic bowel dysfunction to market?
Regulatory bodies require robust clinical evidence demonstrating both efficacy and safety for new neurogenic bowel dysfunction treatments. Considerations include defining appropriate endpoints that reflect meaningful patient outcomes and addressing the heterogeneity of the patient population. Demonstrating a clear benefit-risk profile is paramount for successful market authorization.
Contact Us
📍
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
✉️
For General Inquiry
info@pienomial.com
